Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W N Deininger

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Experimental Hematology|March 24, 2007
Optimizing therapy of chronic myeloid leukemiaMichael W N Deininger
Hematology. American Society of Hematology. Education Program|November 24, 2005
Management of early stage diseaseMichael W N Deininger
Journal of Cancer Research and Clinical Oncology|November 8, 2003
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemiaMichael W N Deininger
Seminars in Hematology|June 5, 2003
Cytogenetic studies in patients on imatinibMichael W N Deininger
Hematology/Oncology Clinics of North America|November 8, 2011
Selection of therapy: rational decisions based on molecular eventsJamshid S Khorashad, Michael W N Deininger
Hematology/Oncology Clinics of North America|July 24, 2004
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformationJunia V Melo, Michael W N Deininger
Pharmacological Reviews|July 19, 2003
Specific targeted therapy of chronic myelogenous leukemia with imatinibMichael W N Deininger, Brian J Druker
Seminars in Hematology|June 5, 2003
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, Michael W N Deininger
Blood|March 5, 2005
Can we afford to let sleeping dogs lie?Michael W N Deininger, Tessa L Holyoake
Cancer Cell|August 25, 2004
SRCircumventing imatinib resistanceMichael W N Deininger, Brian J Druker
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Experimental Hematology|March 24, 2007
Optimizing therapy of chronic myeloid leukemiaMichael W N Deininger
Hematology. American Society of Hematology. Education Program|November 24, 2005
Management of early stage diseaseMichael W N Deininger
Journal of Cancer Research and Clinical Oncology|November 8, 2003
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemiaMichael W N Deininger
Seminars in Hematology|June 5, 2003
Cytogenetic studies in patients on imatinibMichael W N Deininger
Hematology/Oncology Clinics of North America|November 8, 2011
Selection of therapy: rational decisions based on molecular eventsJamshid S Khorashad, Michael W N Deininger
Hematology/Oncology Clinics of North America|July 24, 2004
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformationJunia V Melo, Michael W N Deininger
Pharmacological Reviews|July 19, 2003
Specific targeted therapy of chronic myelogenous leukemia with imatinibMichael W N Deininger, Brian J Druker
Seminars in Hematology|June 5, 2003
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, Michael W N Deininger
Blood|March 5, 2005
Can we afford to let sleeping dogs lie?Michael W N Deininger, Tessa L Holyoake
Cancer Cell|August 25, 2004
SRCircumventing imatinib resistanceMichael W N Deininger, Brian J Druker
Pageof 6